By Denny Jacob

Verrica Pharmaceuticals on Friday said the Food and Drug Administration approved Ycanth topical solution to treat molluscum contagiosum in adults and patients ages two and up.

The dermatology therapeutics company said it plans to make Ycanth available by September.

Molluscum contagiosum is an infection caused by a poxvirus, which can result in a benign, mild skin disease characterized by growths on the body.

Chief Executive Ted White said molluscum contagiosum primarily affects children and is commonly transmitted in households, schools and swimming pools through skin-to-skin contact given its highly contagious nature.

Trading of the company's stock was halted at 3:58 p.m. ET ahead of the news.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

July 21, 2023 16:50 ET (20:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Verrica Parmaceuticals.
Verrica Parmaceuticals (NASDAQ:VRCA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Verrica Parmaceuticals.